High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine

This article reviews the risk of meningococcal disease following eculizumab treatment in patients who have received the meningococcal vaccine.

Saved in:
Bibliographic Details
Published inAmerican journal of transplantation Vol. 17; no. 9; pp. 2481 - 2484
Main Authors McNamara, L. A., Topaz, N., Wang, X., Hariri, S., Fox, L., MacNeil, J. R.
Format Journal Article
LanguageEnglish
Published United States Elsevier Limited 01.09.2017
Subjects
Invasive meningococcal disease
Meningococcal disease
Monoclonal antibodies
Vaccines
Online AccessGet full text

Cover

More Information
Summary:This article reviews the risk of meningococcal disease following eculizumab treatment in patients who have received the meningococcal vaccine.
ISSN:1600-6135
1600-6143
DOI:10.1111/ajt.14426